Uno studio per conoscere l'efficacia di Etrasimod nelle persone con colite ulcerosa (EFFECT-UC)
Efficacia di Etrasimod sull'attività della malattia e sugli esiti riferiti dai pazienti nella colite ulcerosa - EFFECT-UC
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past.
All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device.
The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer.
The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod.
Panoramica dello studio
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Luoghi di studio
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 6J6
- Kelowna Gastroenterology Associates
-
New Westminster, British Columbia, Canada, V3L 3E3
- Columbia Medical Building
-
Richmond, British Columbia, Canada, V7C 5L9
- Richmond Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver Coastal Health
-
Vancouver, British Columbia, Canada, V6Z 2K5
- Providence Health Care (PHC)
-
-
Ontario
-
London, Ontario, Canada, N6A5A5
- London Health Sciences Centre
-
Ottawa, Ontario, Canada, K1H8L6
- Ottawa Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Montreal General Hospital
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM
-
Montreal, Quebec, Canada, H4J 1C4
- Hôpital du Sacré-Cœur de Montréal
-
-
-
-
-
Aachen, Germania, 52064
- MVZ Gastroenterologie Aachen
-
Andernach, Germania, 56626
- Praxis Heil und Müller
-
Berlin, Germania, 10825
- MVZ für Gastroenterologie am Bayerischen Platz
-
Cologne, Germania, 51103
- Evangelisches Krankenhaus Kalk
-
Dachau, Germania, 85221
- MVZ Dachau
-
Frankfurt am Main, Germania, 60594
- Interdisziplinares Crohn Colitis Centrum
-
Grevenbroich, Germania, 41515
- Facharztpraxis für Gastroenterologie
-
Halle, Germania, 06108
- Studiengesellschaft BSF UG.
-
Heidelberg, Germania, 69115
- Praxis für Gasteroenterologie
-
Lübeck, Germania, 23560
- Praxis für Gasteroenterologie Lübeck
-
Lüneburg, Germania, 21339
- Klinikum Lüneburg
-
Oldenburg, Germania, 10115
- Internistische Praxengemeinschaft Oldenburg
-
Remscheid, Germania, 42859
- Magen-Darm-Zentrum Remscheid
-
Wesseling, Germania, 50389
- CED am Rhein
-
-
Breisgau
-
Freiburg im Breisgau, Breisgau, Germania, 79102
- Gastrofreiburg
-
-
Hesse
-
Kassel, Hesse, Germania, 34117
- Gastroenterologie OpernstraBe
-
-
-
-
-
Crumpsall, Regno Unito, M8 5RB
- Northern Care Alliance NHS Foundation Trust, Greater Manchester
-
Kent, Regno Unito, TN2 4QJ
- Tunbridge Wells Hospital
-
London, Regno Unito, SE59RS
- Kings College Hospital
-
London, Regno Unito, NW1 2PG
- University College London Hospital
-
London, Regno Unito, E1 1BB
- Barts Health NHS Trust, The Royal London Hospital
-
London, Regno Unito, HA1 3UJ
- St. Mark's Hospital
-
London, Regno Unito, SE1 7EH
- St Thomas' Hospital - Guy's & St Thomas' NHS Foundation Trust
-
London, Regno Unito, SW17 0QT
- St George's Hospital - St George's Healthcare Nhs Trust
-
London, Regno Unito, W2 1PG
- Imperial College Healthcare NHS
-
Newport, Regno Unito, NP20 2UB
- Royal Gwent Hospital
-
Southampton, Regno Unito, SO16 6YD
- Southampton University Hospitals NHS Trust
-
-
Lanarkshire
-
Glasgow, Lanarkshire, Regno Unito, G4 0SF
- NHS Greater Glasgow and Clyde
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Regno Unito, NG7 2UH
- Nottingham University Hospitals NHS Trust, Queens Medical Centre
-
-
Oxfordshire
-
Oxford, Oxfordshire, Regno Unito, OX3 9DU
- Oxford University Hospitals NHS Foundation Trust
-
-
Scotland
-
Edinburgh, Scotland, Regno Unito, EH4 2XU
- Western General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the local approved label and independent from the decision to enroll the patient in this study.
Descrizione
Inclusion Criteria:
- Male and female patients ≥18 and <65 years of age at baseline
- Patients with confirmed diagnosis of ulcerative colitis and who are prescribed etrasimod for moderately to severely active ulcerative colitis as per the product label independently of the decision to enroll a patient in this study.
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
Exclusion Criteria:
-
Presence of clinical findings suggestive of Crohn's disease.
-
Severe extensive colitis evidenced by:
-
Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (eg, colectomy) within 12 weeks.
-
Current evidence of acute severe UC, fulminant colitis, or toxic megacolon 3. Patients with a stoma or planned UC surgical intervention requiring hospitalization.
4. Prior/Concomitant Therapy:
- any previous exposure to etrasimod including participation in the etrasimod clinical program.
- any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine or tioguanine) or with any of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist); JAK inhibitors (filgotinib, tofacitinib or upadacitinib) or with any other S1P receptor modulator.
-
-
Not owning a digital device with internet connection and/or not willing to complete health questionnaires on this device or not capable of using the health questionnaire collection tool.
-
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Pazienti in trattamento con etrasimod per colite ulcerosa
|
As provided in real world practice |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients with symptomatic remission
Lasso di tempo: Week 12
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. |
Week 12
|
|
Proportion of patients with symptomatic remission
Lasso di tempo: Week 52
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. |
Week 52
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients with clinical response
Lasso di tempo: Week 12
|
Clinical response was defined as decrease of at least 20% in Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2) from baseline or achievement of symptomatic remission. |
Week 12
|
|
Proportion of patients with clinical response.
Lasso di tempo: Week 52
|
Clinical response was defined as decrease of at least 20% in Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2) from baseline or achievement of symptomatic remission. |
Week 52
|
|
Proportion of corticosteroid-free patients with symptomatic remission
Lasso di tempo: Week 52
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. Patients have to be corticosteroid-free for at least 12 weeks prior to the visit. |
Week 52
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Pfizer CT.gov Call Center, Pfizer
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- C5041041
- EFFECT-UC (Altro identificatore: Alias Study Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .